Risperidone
DrugAs prescribed by routine prescriber (not dictated by study protocol)
Other names: Risperdal, Risperdal Consta
NCT Number: NCT00044655
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Over the past several years, new, "atypical" antipsychotic medications have become available to treat schizophrenia with little information to guide prescribing for relatively stable outpatients.
Participants will be randomly assigned to either continue taking their current medications for schizophrenia, or to switch to a new medication. Participants assigned to switch to a new medication will begin receiving either olanzapine (Zyprexa), risperidone (Risperdal), ziprasidone (Geodon), quetiapine (Seroquel), or aripiprazole (Abilify), depending on what they are currently taking. Participants currently taking a single oral medication will switch to olanzapine, risperidone, ziprasidone, quetiapine, or aripiprazole. Participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone (Risperdal Consta). Participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using. Participants will stay on their assigned treatment for 6 months, after which time the participant's prescribing psychiatrist will advise the participant on which medication should be used. Study participants are interviewed at study start and at follow-up visits for 1 year.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
As prescribed by routine prescriber (not dictated by study protocol)
Other names: Risperdal, Risperdal Consta
As prescribed by routine prescriber (not dictated by study protocol)
Other names: Zyprexa
As prescribed by routine prescriber (not dictated by study protocol)
Other names: Geodon
As prescribed by routine prescriber (not dictated by study protocol)
Other names: Seroquel
As prescribed by routine prescriber (not dictated by study protocol)
Other names: Abilify
Time frame: Measured at Six Months
Time frame: during first 6 months
Number of participants hospitalized for psychiatric reasons
Icahn School of Medicine at Mount Sinai
Other
Effectiveness of Switching Antipsychotic Medications
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05838573
Cognition Disorders, Cognitive Dysfunction
Changsha, Hunan, China
View Trial DetailsNCT05304767
Mental Disorders, Schizophrenia
Phoenix, Arizona, United States
View Trial DetailsNCT00004571
Mental Disorders, Normal Physiology
Bethesda, Maryland, United States
View Trial DetailsNCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial Details